Prospective Phase II Study of Stereotactic Body Proton Therapy for Treatment of PrimAry Renal Cell Carcinoma (SPARE)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Summary
This study examines the impact of proton based stereotactic radiation therapy (SBRT) on kidney function as well as other oncologic outcomes including local control, locoregional and systemic failure, progression free and overall survival.
Description
The incidence of kidney cancer diagnosis has been increasing over the last years. Surgical resection represents the mainstay treatment. However, many patients are deemed unfit for surgery due to medical comorbidities or technical limitations. There are non-surgical options including active surveillance, cryotherapy, microwave ablation, radiofrequency and stereotactic radiation therapy (SBRT). SBRT using conventional x-rays has recently been shown to improve outcomes for patients with primary renal cell carcinoma (RCC) in terms of local control and toxicity. However, this treatment was associat…
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Age ≥ 18 years 2. Biopsy proven renal cell carcinoma. 3. No clinical or radiographic evidence of metastatic disease. 4. Not a candidate for surgical treatment or local ablative procedures. 5. Subjects are able to undergo either an MRI or administration of contrast agent for CT. Exclusion Criteria: 1. Prior history of radiation treatment with overlapping fields. 2. Patients with proven metastatic disease. 3. Female subjects who are pregnant or planning to become pregnant during the treatment.
Interventions
- RadiationProton Stereotactic Body Radiation therapy (SBRT)
Radiation therapy will consist of 3-5 treatments over 1.5 - 2 weeks
Location
- Sibley Memorial HospitalWashington D.C., District of Columbia